HealthCap’s investment objective is to achieve significant capital appreciation by focusing on diseases with high unmet medical needs and breakthrough therapies. A cornerstone of the strategy is to invest in companies developing therapeutic interventions that have the potential to significantly improve patient outcomes. HealthCap funds are looking to back companies developing targeted therapies for rare diseases (orphan drugs), cancer and genetic diseases, among others. HealthCap has substantial experience in assisting start-ups and emerging companies growing into businesses ready for initial public offerings or trade sales. HealthCap funds will not make an investment unless there are realistic avenues to make a timely exit at an attractive return.
Investment Criteria
Investment opportunities are analyzed based on, among others, the following criteria:
- Addressing unmet medical needs
- High degree of innovation / breakthrough therapies
- Adding value to the health care sector / reimbursement strategy
- Strong intellectual property rights
- Clear regulatory strategy
- Attractive to strategic partners
- Beneficial risk / return profile
- Capital efficient business model
- High quality management